IN THE CLAIMS

Claims presented previously and new claims added herein are presented below with parenthetical status notations. An instruction line precedes each claim that is amended or added by the instant paper.

Please **amend** claim 1 as follows:

1. [CURRENTLY AMENDED] A process for detecting threonine or serine kinase activity in an immunoassay comprising ~~the following steps~~:

a) providing a threonine or serine kinase substrate protein or peptide comprising the sequence motif

-Z-X-Y or -Y-X-Z-

wherein

Z = threonine or serine

X = a sequence of amino acids, preferably between 1 and 1000 amino acids, which may be the same or different

Y = phospho-tyrosine, phospho-threonine or phospho-serine;

Dcont'd.

~~as a substrate for threonine or serine kinase,~~

~~said protein or peptide being pre phosphorylated~~

~~at the Y position;~~

b) incubating the protein or peptide with a phosphate donor and a threonine or serine kinase to form a protein or peptide which is phosphorylated at positions Y and Z;

c) adding an antibody having a specificity to a peptide or protein which is phosphorylated at the Y and Z position; and

d) detecting the threonine or serine kinase activity.

2. [ORIGINAL] The process according to claim 1, wherein the phosphate donor is ATP, GTP, or a synthetic cosubstrate.

Please **amend** claim 3 as follows:

3. [CURRENTLY AMENDED] The process according to claim 1, wherein the immunoassay is performed as a direct binding immunoassay~~, preferably a homogeneous direct binding immunoassay~~.

Please **amend** claim 4 as follows:

4. [CURRENTLY AMENDED] The process according to claim 3, wherein ~~a labelled~~said peptide or protein ~~is used as~~further comprises a ~~substrate~~molecular label.

Please **amend** claim 5 as follows:

5. [CURRENTLY AMENDED] The process according to claim 3, wherein ~~a labelled~~said antibody ~~is used~~further comprises a molecular label.

Please **amend** claim 6 as follows:

6. [CURRENTLY AMENDED] The process according to claim 4, wherein ~~the peptide/protein or antibody~~said label is ~~labelled by~~selected from the group consisting of a luminescent tag, a radioactive marker, a reporter enzyme, ~~or~~and an affinity ligand.

Please **amend** claim 7 as follows:

7. [CURRENTLY AMENDED] The process according to claim 1, wherein the immunoassay is performed as an indirect

binding immunoassay~~, preferably a homogenous indirect binding immunoassay~~.

Please amend claim 8 as follows:

8. [CURRENTLY AMENDED] The process according to claim ~~7,~~ ~~wherein a labelled ligand which is phosphorylated at its Y and Z position (bis phosphorylated ligand) is added to compete with the protein or peptide which is phosphorylated at its Y and Z position (bis phosphorylated ligand) for binding to the antibody.~~ 7 further comprising:

e) adding a competitor protein or competitor peptide comprising the sequence motif

-Z'-X'-Y' or -Y'-X'-Z'-

wherein

Z' = phospho-threonine or phospho-serine

X' = a sequence of amino acids, preferably between 1 and 1000 amino acids, which may be the same or different

Y' = phospho-tyrosine, phospho-threonine or phospho-serine.

Please **amend** claim 9 as follows:

9. [CURRENTLY AMENDED] The process according to claim 8, wherein the ~~bis phosphorylated ligand is labelled by~~competitor protein or competitor peptide further comprises a label selected from the group consisting of a luminescent tag, a radioactive marker, a reporter enzyme, ~~or~~and an affinity ~~legend~~tag.

Please **amend** claim 10 as follows:

10. [CURRENTLY AMENDED] The process according to claim 9, wherein the ~~ligand~~competitor protein or competitor peptide comprises the amino acid sequence of SEQ ID NO:43 such that said sequence motif is

-Y'-X'-Z'-

wherein

Y' is phosphorylated ~~at amino acids~~ Tyr[5] ~~and 7, and particular is~~of SEQ ID NO:~~4 that~~3,

X' is Pro^6 of SEQ ID NO:3, and

Z' is phosphorylated ~~at amino acids 5 and~~ Thr^7 ~~and has 5-TAMRA-AEEA at the carboxy terminus.~~of SEQ ID NO:3.

Please **amend** claim 11 as follows:

11. [CURRENTLY AMENDED] The process according to claim 1, wherein ~~the assay~~said d) detecting threonine or serine kinase activity is ~~performed as a~~achieved by fluorescence ~~immunoassay~~detection, ~~in particular a~~ fluorescence polarization ~~immunoassay~~analysis, ~~a~~ fluorescence correlation ~~spectroscopic assay~~spectroscopy, ~~a~~ fluorescence resonance energy transfer ~~assay~~analysis, or ~~a~~ fluorescence intensity distribution ~~assay~~analysis.

Please **amend** claim 12 as follows:

12. [CURRENTLY AMENDED] The process according to claim 1, wherein X in the sequence motif comprises proline or glutamate or glycine or combinations thereof.

Please amend claim 13 as follows:

13. [CURRENTLY AMENDED] The process according to claim 1, wherein the threonine or serine kinase substrate protein or peptide provided is selected from the group consisting of the active site loop of JNK1, the active site loop of JNK~~2 or~~2, and the active site loop of JNK~~3 protein.~~3.

Please amend claim 14 as follows:

14. [CURRENTLY AMENDED] The process according to claim ~~1,~~13, wherein the threonine or serine kinase substrate protein or peptide provided ~~includes sequences identical to those~~is selected from the group consisting of JNK1, JNK~~2~~2, ~~or~~and JNK~~3 active site loop.~~3.

Please amend claim 15 as follows:

15. [CURRENTLY AMENDED] The process according to claim 1, wherein the substrate protein or substrate peptide comprises the amino acid sequence of SEQ ID NO:2 such that said sequence motif is

-Y-X-Z-

wherein ~~amino acid 5~~

Y is phosphorylated~~.~~ Tyr[5] of SEQ ID NO:2,

X is Pro[6] of SEQ ID NO:2, and

Z is Thr[7] of SEQ ID NO:2.

Please **cancel** claim 16 without prejudice.

16. [CANCELLED]

Please **amend** claim 17 as follows:

17. [CURRENTLY AMENDED] The process according to claim 1, wherein the ~~incubation of the protein~~threonine or ~~peptide~~serine kinase is ~~carried out in the presence of~~ a threonine kinase.

Please **amend** claim 18 as follows:

18. [CURRENTLY AMENDED] The process according to claim 17, wherein the threonine kinase is a mitogen-

activated protein kinase kinase ~~(MKK) (also named stress activated protein kinase kinase, SKK)~~.

Please **amend** claim 19 as follows:

19. [CURRENTLY AMENDED] The process according to claim 18, wherein the kinase is MKK~~7 (also named SKK4)~~ 7.

20. [ORIGINAL] The process according to claim 1, wherein the antibody is a monoclonal or polyclonal antibody.

21. [ORIGINAL] The process according to claim 20, wherein the antibody is a polyclonal antibody.

Please **amend** claim 22 as follows:

22. [CURRENTLY AMENDED] The process according to claim 21, wherein the antibody is a polyclonal antibody specific for bis-phosphorylated~~, in particular~~ active JNK.

23. [ORIGINAL] The process according to claims 1, wherein steps a) to d) are performed sequentially.

Please **amend** claim 24 as follows:

24. [CURRENTLY AMENDED] A kit for detecting threonine or serine kinase activity in an immunoassay comprising the following components:

a substrate as defined in claim 1; and

an antibody as defined in claim ~~1; and~~1.

Please **amend** claim 25 as follows:

25. [CURRENTLY AMENDED] The kit according to claim 24 further comprising a threonine or serine kinase~~,~~ and/or a reaction ~~buffers~~buffer ~~including~~comprising a phosphate donor~~, preferably ATP~~.

Please **amend** claim 26 as follows:

26. [CURRENTLY AMENDED] The kit according to claim 24 further comprising a labelled ~~ligand, preferably luminescently labelled ligand, said ligand~~competitor protein or labelled competitor peptide comprising the ~~following~~ sequence motif

~~-Z-X'-X'-Y' or - or Y-X-Z-~~

~~wherein~~

~~Z = threonine or serine~~

~~X = a sequence of amino acids, preferably between 1 and 1000 amino acids, which may be the same or different~~

~~Y = tyrosine,~~ Y'-X'-Z'-

wherein

Z' = phospho-threonine or phospho-serine

~~said protein or peptide ligand being phosphorylated at the Z and Y positions;~~

X' = a sequence of amino acids, preferably between 1 and 1000 amino acids, which may be the same or different

Y' = phospho-tyrosine, phospho-threonine or phospho-serine.

Please cancel claim 27 without prejudice.

27. [CANCELLED]

Please **cancel** claim 28 without prejudice.

28. [CANCELLED]

Please **add** new claim 29 as follows:

29. [NEW] A immunoassay for screening modulators of threonine or serine kinase activity comprising:

a) providing a threonine or serine kinase substrate protein or peptide comprising the sequence motif

-Z-X-Y or -Y-X-Z-

wherein

Z = threonine or serine

X = a sequence of amino acids, preferably between 1 and 1000 amino acids, which may be the same or different

Y = phospho-tyrosine, phospho-threonine or phospho-serine;

b) incubating the protein or peptide with a phosphate donor and a threonine or serine kinase

to form a protein or peptide which is phosphorylated at positions Y and Z;

c) adding an antibody having a specificity to a peptide or protein which is phosphorylated at the Y and Z position;

d) adding a test compound;

e) detecting the threonine or serine kinase activity; and

f) comparing the threonine or serine kinase activity in the presence of the test compound with the threonine or serine kinase activity in the absence of the test compound,

wherein altered threonine or serine kinase activity in the presence of the test compound relative to threonine or serine kinase activity in the absence of the test compound indicates a modulator of threonine or serine kinase activity.

Please **add** new claim 30 as follows:

30. [NEW] The method of claim 29, wherein a threonine or serine kinase inhibitor is indicated by lower threonine or serine kinase activity in the presence of the test compound relative to the threonine or serine kinase activity in the absence of the test compound.

Please **add** new claim 31 as follows:

31. [NEW] The process according to claim 3, wherein the direct binding immunoassay is a homogeneous direct binding immunoassay.

Please **add** new claim 32 as follows:

32. [NEW] The process according to claim 5, wherein said label is selected from the group consisting of a luminescent tag, a radioactive marker, a reporter enzyme, and an affinity ligand.

Please **add** new claim 33 as follows:

33. [NEW] The process according to claim 7, wherein the indirect binding immunoassay is a homogenous indirect binding immunoassay.

Please **add** new claim 34 as follows:

34. [NEW] The process according to claim 10, wherein the competitor protein or competitor peptide further comprises 5-TAMRA-AEEA at the carboxy terminus.

Did cond'd.

Please **add** new claim 35 as follows:

35. [NEW] The kit according to claim 25, wherein the phosphate donor is ATP.